Edgewell Personal Care (EPC) Q4 2025 earnings review
Transformation Amidst a Margin Shock
Edgewell closed FY25 with a strategic pivot, announcing the $340M divestiture of its struggling Feminine Care business. While Q4 organic sales beat expectations (+2.5%), the bottom line crumbled. Adjusted Gross Margin collapsed 330 basis points to 39.3% due to 'transitory' inventory adjustments and promotions. Consequently, Adjusted EPS fell 6% to $0.68. Looking ahead, the FY26 outlook indicates an earnings recession, with EPS guided down ~10% at the midpoint ($2.35) as tariffs and reinvestment costs outweigh productivity gains.
🐂 Bull Case
The sale of Feminine Care for $340M removes a drag on growth (segment profit fell ~23% in Q4) and allows management to focus on 'Right-to-Win' categories like Grooming and Sun Care. Proceeds will reduce leverage toward the 3.0x target.
International markets remain a fortress, growing organic sales for the 14th consecutive quarter. While North America struggles, international now represents ~40% of sales and continues to gain share in key markets like Japan and Germany.
🐻 Bear Case
The unexpected 330 bps drop in Adjusted Gross Margin in Q4 raises questions about operational visibility. Management blamed 'transitory' inventory adjustments at the Mexico plant, but with Q1 FY26 also guided for a loss, the 'transitory' narrative faces a trust deficit.
FY26 guidance includes a significant $25M net tariff headwind (~$0.55/share). Management admitted the U.S. market is 'not conducive to price increases,' meaning these costs will directly hit the P&L without a top-line offset.
⚖️ Verdict: 🔴
Bearish. The Feminine Care divestiture is the right long-term move, but the immediate financial picture is ugly. A surprise margin collapse in Q4, combined with guidance for declining earnings and a Q1 loss in FY26, suggests the 'transition' will be painful and risky.
Key Themes
Gross Margin Collapse
Adjusted Gross Margin fell from 42.6% last year to 39.3% in Q4—a massive 330 bps contraction. Management cited inventory adjustments from the Mexico plant consolidation and higher trade promotions. While described as one-off, this level of volatility in a core metric is alarming.
International Growth Engine
International sales grew 6.9% organically in Q4, marking steady performance even as the U.S. business (down 0.6%) faltered. This segment has grown for four straight years and acts as the primary stabilizer for the company's top line.
Tariffs & Inflation Headwinds
The FY26 outlook is heavily burdened by external costs. Tariffs are projected to cost $37M gross ($25M net of mitigation). When combined with general inflation, Edgewell faces a steep uphill battle to protect margins, especially given their admission of limited pricing power in the U.S.
Manufacturing Consolidation
Management is betting the house on productivity, targeting 310 bps of gross savings in FY26. A key driver is the consolidation of four North American Wet Shave facilities into a single automated plant. This is high-risk, high-reward execution required to fund marketing investments.
Q1 FY26 Profit Warning
Management explicitly guided for a reported EPS loss in the upcoming Q1 FY26. They attribute this to the timing of marketing spend and the trough of margin pressure. A guided loss immediately following a margin miss creates significant execution pressure for the second half of the year.
Other KPIs
Decelerating. Down 28% from $56.0M in the prior year period. Operating margin compressed to 7.5% from 10.8%, driven by the gross margin shock and sustained SG&A/A&P spending.
Decelerating. Down 15% YoY from $62.2M, despite sales being roughly flat ($321.9M vs $318.2M). This indicates negative operating leverage and rising input costs in the core profit driver.
A non-cash goodwill impairment charge specifically related to the Feminine Care unit, triggered by the valuation implied by the divestiture announcement. This dragged GAAP Net Income to a loss of $(30.6)M.
Guidance
Decelerating. The midpoint ($2.35) represents a ~7% decline from FY25's $2.52. This outlook is weighed down by the Fem Care divestiture dilution ($0.40-$0.50 annualized impact) and tariff costs, only partially offset by buybacks and productivity.
Stable. The range brackets the FY25 result (-1.3%). Management expects mid-single-digit international growth to offset flat-to-down North American performance.
Stable. The midpoint ($300M) is effectively flat vs FY25's $301M. This implies that all productivity gains (aimed at +310 bps) will be consumed by inflation, tariffs, and marketing reinvestment rather than dropping to the bottom line.
Accelerating. A significant improvement from the depressed FY25 level (~$40M derived), assuming working capital normalizes after FY25's inventory builds for tariff mitigation.
Key Questions
Margin Visibility
Given the 'transitory' inventory adjustments that caused a 330 bps margin miss in Q4, what specific controls are in place to prevent similar surprises during the massive North American manufacturing consolidation planned for FY26?
North America Turnaround Confidence
You are guiding Q1 FY26 organic sales down 1-2%. With North American turnarounds historically taking longer than expected, what specific KPIs (beyond sales) suggest the new leadership team is gaining traction?
Tariff Mitigation vs Pricing
You stated the US market is 'not conducive' to price increases. Does this imply the $25M net tariff impact is a permanent structural margin step-down if productivity savings falter?